NCT02093429View on ClinicalTrials.gov

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

MDS (Myelodysplastic Syndrome)

Interventions

DRUG

INCB047986

INCB047986 will be supplied as tablets.

Trial Locations (7)

Unknown

Highland

Indianapolis

Morristown

Somerville

Germantown

Houston

Burlington

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY